betaxolol has been researched along with Cardiac Failure in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " with NYHA II or III heart failure were double-blind randomized and uptitrated to either carvedilol 25 mg bid (n=131) or betaxolol 20 mg od (n=124)." | 9.12 | Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). ( Chochola, J; Figulla, HR; Fridl, P; Kalmbach, C; Krzeminska-Pakula, M; Wrabec, K, 2006) |
| "The cardioprotective effects of betaxolol were studied in a rat model with heart failure induced by autoimmune myocarditis." | 7.72 | Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure. ( Aizawa, Y; Hasegawa, G; Inoue, M; Juan, W; Kodama, M; Ma, M; Naito, M; Nakazawa, M; Narasimman, G; Saito, Y; Tachikawa, H; Takahashi, T; Tanabe, N; Wahed, MI; Watanabe, K; Yamaguchi, K; Yamamoto, T, 2003) |
| " with NYHA II or III heart failure were double-blind randomized and uptitrated to either carvedilol 25 mg bid (n=131) or betaxolol 20 mg od (n=124)." | 5.12 | Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). ( Chochola, J; Figulla, HR; Fridl, P; Kalmbach, C; Krzeminska-Pakula, M; Wrabec, K, 2006) |
| "The cardioprotective effects of betaxolol were studied in a rat model with heart failure induced by autoimmune myocarditis." | 3.72 | Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure. ( Aizawa, Y; Hasegawa, G; Inoue, M; Juan, W; Kodama, M; Ma, M; Naito, M; Nakazawa, M; Narasimman, G; Saito, Y; Tachikawa, H; Takahashi, T; Tanabe, N; Wahed, MI; Watanabe, K; Yamaguchi, K; Yamamoto, T, 2003) |
| "Carvedilol was prescribed in 7 331 patients treated for HF (9." | 1.62 | Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic. ( Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M, 2021) |
| "Carvedilol was shown to be well tolerated and effective in elderly heart failure patients in the observational COLA II study." | 1.32 | Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. ( Clark, AL; Cleland, JG; Coletta, AP; Freemantle, N, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Taborsky, M | 1 |
| Aiglova, R | 1 |
| Lazarova, M | 1 |
| Pavlu, L | 1 |
| Danek, J | 1 |
| Precek, J | 1 |
| Schee, A | 1 |
| Gloger, V | 1 |
| Vicha, M | 1 |
| Skala, T | 1 |
| Watanabe, K | 1 |
| Juan, W | 1 |
| Narasimman, G | 1 |
| Ma, M | 1 |
| Inoue, M | 1 |
| Saito, Y | 1 |
| Wahed, MI | 1 |
| Nakazawa, M | 1 |
| Hasegawa, G | 1 |
| Naito, M | 1 |
| Tachikawa, H | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Yamamoto, T | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 1 |
| Coletta, AP | 1 |
| Cleland, JG | 1 |
| Freemantle, N | 1 |
| Clark, AL | 1 |
| Figulla, HR | 2 |
| Krzeminska-Pakula, M | 1 |
| Wrabec, K | 1 |
| Chochola, J | 1 |
| Kalmbach, C | 1 |
| Fridl, P | 1 |
| Böhler, S | 1 |
| Saubadu, S | 1 |
| Scheldewaert, R | 1 |
| Waldock, A | 1 |
| Snape, J | 1 |
| Graham, CM | 1 |
| Herschman, Z | 1 |
| Kaufman, B | 1 |
| Ball, S | 1 |
3 trials available for betaxolol and Cardiac Failure
| Article | Year |
|---|---|
Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Double-Blin | 2006 |
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Chronic Disease; Double | 1999 |
Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Betaxolol; Blood | 2000 |
5 other studies available for betaxolol and Cardiac Failure
| Article | Year |
|---|---|
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Fa | 2021 |
Betaxolol improves the survival rate and changes natriuretic peptide expression in rats with heart failure.
Topics: Animals; Atrial Natriuretic Factor; Betaxolol; Gene Expression Regulation; Heart Failure; Male; Rats | 2003 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Clinical | 2004 |
Complications arising from the use of ophthalmologic medications in an intensive care unit patient.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Bronchial Spasm; Female; Heart Failure; Humans; Intens | 1989 |
Congestive heart failure from betaxolol. Case report.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Betaxolol; Glaucoma, Open-Angle; Heart Failure | 1987 |